XTrend
MenuXTrend

Stock Charts

Charts can help you clearly see the market trend.

JNJ

Johnson & Johnson

Bid154.36
Ask154.53
Change-1.93
% Chg -1.23%
High155.07
Low153.26

Past performance is not an indication of future results.

About

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Industry

Pharmaceuticals

Stock Exchange

NYSE

Listing Date

25-09-1944

Trading Specifications
Minimum Price Fluctuation
--
Spreads as low as
--
Average Spreads
--
Minimum Lot Size
--
Commission
--
Trading Hours(GMT+2)
--
Maximum Trading Volume (lots)
--
News
Goldman Sachs updates conviction lists: Adds Johnson & Johnson and Axis Bank
FDA approves new treatment for myasthenia gravis
Johnson & Johnson receives FDA approval for IMAAVY
Sandoz shares down as Q1 sales fall short on biosimilar weakness
Nvidia, JNJ, Toyota chiefs among White House guests for investment event- report
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
Johnson & Johnson retains ’AAA’ rating at S&P, credit outlook stable
Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
XTrend

AFA REGIONAL SPONSOR

XTrendEnglish
XTrend
XTrend
XTrend
XTrend
XTrend